AMENDMENTS TO THE CLAIMS

1. (**Currently Amended**) A peptide-lipid complex in an aqueous solution, wherein said lipid is a bilayer-forming galactolipid material and that the weight ratio between the peptide and the galactolipid material is 1:5 – 1:50, with the proviso that the peptide is not LL-37 (SEQ ID NO: 1).

2. (Previously Presented) The method according to claim 22, wherein the weight ratio between the peptide and the galactolipid material is 1:10 - 1:50.

3. (Previously Presented) The method according to claim 22, wherein said peptide is a charged and amphiphilic peptide having a molecular weight below 30 kDa.

4. (Previously Presented) The method according to claim 22, wherein the peptide has at least four positively charged amino acids.

5. (Previously Presented) The method according to claim 22, wherein the peptide is in the form of a pharmaceutically acceptable salt.

6. (Previously Presented) The method according to claim 22, wherein the galactolipid material is a polar lipid mixture rich in digalactosyldiacylglycerols.

7. (Previously Presented) The method according to claim 22, wherein the galactolipid material is CPL-Galactolipid.

8. (Previously Presented) The method according to claim 22, wherein the peptide is an apolipoprotein or an apolipoprotein analogue.

9. (Previously Presented) The method according to claim 22, wherein the peptide is selected from the group consisting of insulin, glucagon, erythropoietin, darbepoietin, streptokinase, somatropin, desmopressin, oxytocin, gonadorelin, nafarelin, octreotid, lanreotid, ganirelix, cetrorelix, teriparalid, and salmon calcitonin.

10. (Previously Presented) The method according to claim 22, wherein the peptide is selected from the group consisting of magainin 2, cecropin, and histatin.

11. (Previously Presented) The method according to claim 22, wherein said peptide is a cationic antimicrobial peptide having a molecular weight of 2.5 - 5 kDa.

12. (Previously Presented) The method according to claim 22, having a peptide:galactolipid weight ratio of 1:10 – 1:27.

13. (**Currently Amended**) The method according to claim 22, wherein the peptide is selected from the group consisting of LL-25 (SEQ ID NO: 13), LL-26 (SEQ ID NO: 12), LL-27 (SEQ ID NO: 11), LL-28 (SEQ ID NO: 10), LL-29 (SEQ ID NO: 9), LL-30 (SEQ ID NO: 8), LL-31 (SEQ ID NO: 7), LL-32 (SEQ ID NO: 6), LL-33 (SEQ ID NO: 5), LL-34 (SEQ ID NO: 4), LL-35 (SEQ ID NO: 3), LL-36 (SEQ ID NO: 2), and LL-38 (SEQ ID NO: 14).

14. (**Currently Amended**) The method according to claim 22, comprising the peptide LL-25 (SEQ ID NO: 13) and a galactolipid material.

15. (Previously Presented) A colloidal solution of the medicament composition according to claim 19, wherein the mean size of said complexes of said ingredient (a) is below 100 nm.

16. (**Currently Amended**) A colloidal solution of a complex between LL-37 (SEQ ID NO: 1) and a bilayer-forming galactolipid material, wherein the mean size of said complexes is below 100 nm.

17. – 18. (Cancelled)

19. (**Currently Amended**) A medicament composition comprising

(a) a peptide-lipid complex in an aqueous solution, wherein said lipid is a bilayer-forming galactolipid material and that the weight ratio between the peptide and the galactolipid material is 1:5 – 1:50, with the proviso that the peptide is not LL-37 (SEQ ID NO: 1); or

(b) a complex between LL-37 (SEQ ID NO: 1) and a bilayer-forming galactolipid material, wherein the mean size of said complexes is below 100 nm.

20. (Previously Presented) A method of treating infections, wound healing or other diseases with a deficiency in antimicrobial activity comprising:

treating a patient in need thereof with a composition according to claim 19.

21. (Cancelled)

22. (Previously Presented) The method of claim 20, which comprises treating a patient in need thereof with said ingredient (a).

23. (Previously Presented) The method of claim 20, which comprises treating a patient in need thereof with said ingredient (b).